- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05421806
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/ (DrEW)
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe
Following the initiation of Doravirine (DOR) regimen among people living with HIV (PLWH), the study will aim to assess effectiveness, discontinuation, and resistance over the 12-month period.
Retrospective data from 400 patients, 100 treatment naïve and 300 virally suppressed patients switching from a 1st or second line treatment, is planned to be collected from 6 - 10 European sites.
The study will be conducted through collaboration with the NEAT ID Network, a well-established network of clinical sites across Europe.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: DREW Project Manager
- Phone Number: +44 203 859 7747
- Email: drew@rokcservices.com
Study Locations
-
-
-
Nantes, France
- CHU de Nantes
-
Paris, France
- St Louis Hospital
-
Paris, France
- Hôpital Universitaire Pitié-Salpêtrière
-
-
-
-
-
London, United Kingdom
- Guy's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- are HIV positive male or female
- are aged ≥18 years
- were prescribed and received at least one dose of DOR (without initial dose adjustment).
- have started/been switched to DOR for at least 12 months at time of data collection
- had a resistance genotype available before starting DOR
- had no evidence of DOR-associated resistance mutation
- were on DOR containing ART regimen that also contained 2 fully active nucleos(t)ides and patient had no documented NRTI resistance mutations to the two NRTIs in the combination.
Patients who, at the time of initiation, were:
- Category 1: HIV treatment naïve OR
- Category 2: Virologically suppressed (HIV-1 RNA <50 copies/mL) for at least 6 months with no evidence of prior virological failure with agents of the NNRTI class
Patients in category 1 and 2 above who have NNRTI mutations that do not impact on DOR (K103N, Y181C, and G190A) using the Stanford algorithm (https://hivdb.stanford.edu/hivdb/by-mutations) can be included in this study.
Exclusion Criteria:
- Patients who have DOR as part of their fourth line or higher therapy
- Patients with prior virological failure with agents of the NNRTI class
- Patients with no documented resistance testing.
- Patients with no genotype available at DOR initiation
- Patients enrolled in DOR trials
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
---|
Treatment naive
|
Treatment switched
Virologically suppressed (VL < 50 copies for more than 6 months)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients, virologically suppressed/undetectable (<50 copies/mL) at week 48 who have remained on DOR.
Time Frame: Week 48 after DOR initiation
|
Week 48 after DOR initiation
|
|
Proportion of patients with virologic failure (Cohort 1 - treatment naive)
Time Frame: on or after week 48 after DOR initiation
|
i. Two consecutive HIV RNA VL levels ≥50 copies/mL after reaching at HIV RNA < 50 copies/mL or ii.
One HIV RNA VL level ≥50 copies/mL and DOR regimen is discontinued immediately or at next hospital visit, after reaching HIV RNA < 50 copies/mL
|
on or after week 48 after DOR initiation
|
Proportion of patients with virologic failure (Cohort 2 - treatment suppressed)
Time Frame: up to 12 months after initiation of DOR
|
i. Two consecutive HIV RNA VL levels ≥50 copies/mL after reaching at HIV RNA < 50 copies/mL or ii.
One HIV RNA VL level ≥50 copies/mL and DOR regimen is discontinued immediately or at next hospital visit, after reaching HIV RNA < 50 copies/mL
|
up to 12 months after initiation of DOR
|
Proportion of patients switched for reasons other than virological failure.
Time Frame: up to 12 months after initiation of DOR
|
up to 12 months after initiation of DOR
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with confirmed virologic failure, commonly used to make treatment related clinical decisions (Cohort 1 - treatment naive)
Time Frame: on or after week 48 after DOR initiation
|
i. Two consecutive HIV RNA VL levels ≥200 copies/mL after reaching HIV RNA < 200 copies/mL or ii.
One HIV RNA VL level ≥200 copies/mL and DOR regimen is discontinued immediately or at next hospital visit, after reaching HIV RNA < 200 copies/mL.
|
on or after week 48 after DOR initiation
|
Proportion of patients with confirmed virologic failure, commonly used to make treatment related clinical decisions (Cohort 1 - treatment naive)
Time Frame: up to 12 months after initiation of DOR
|
i. Two consecutive HIV RNA VL levels ≥200 copies/mL after reaching HIV RNA < 200 copies/mL or ii.
One HIV RNA VL level ≥200 copies/mL and DOR regimen is discontinued immediately or at next hospital visit, after reaching HIV RNA < 200 copies/mL.
|
up to 12 months after initiation of DOR
|
Estimated proportion of patients with low level viremia (≥50-<200 copies/mL)
Time Frame: up to 12 months after initiation of DOR
|
up to 12 months after initiation of DOR
|
|
HIV resistance mutations subtypes for all DOR treated patients with virologic failure
Time Frame: during the 12-month data collection period.
|
during the 12-month data collection period.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Anton Pozniak, Chelsea and Westminster NHS Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NEAT1010
- NEAT 1010 (Other Identifier: NEAT ID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV I Infection
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
University of ConnecticutMedical Research Council, South AfricaRecruitingHIV I InfectionUnited States
-
Hospital Civil de GuadalajaraCompleted
-
State University of New York - Downstate Medical...National Institute of Mental Health (NIMH); Yale UniversityEnrolling by invitationHIV I InfectionUnited States
-
Bionor Immuno ASCelgene CorporationCompleted
-
Bionor Immuno ASCompletedHIV I InfectionGermany, United States, Spain, United Kingdom, Italy
-
Biomedical Research and Training Institute, ZimbabweGilead SciencesCompletedHIV I Infection | ARTZimbabwe